|Articles|October 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-10-01-2001
  • Volume 0
  • Issue 0

Oncology: EMEA Approval Lags

Author(s)Kevin Gopal

London-European cancer patients are losing out because current processes for reviewing treatments are "dire," says the Cancer Research Campaign.

Articles in this issue

about 24 years ago

PBMs: Merck-Medco in the Hot Seat

about 24 years ago

Weak Bones, Strong Market

about 24 years ago

Approvals: Novartis’ Silver Lining

about 24 years ago

Pfizer and others Pitch In

about 24 years ago

Illegal Sales in India

about 24 years ago

Little Elan Becomes a Big Deal

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.